Multi-scale influences on Escherichia coli concentrations in shellfish: From catchment to estuary.

Sustainability of bivalve shellfish farming relies on clean coastal waters, however, high levels of faecal indicator organisms (FIOs, e.g. Escherichia coli) in shellfish results in temporary closure of shellfish harvesting beds to protect human health, but with economic consequences for the shellfish industry.

Soil carbon in the world's tidal marshes.

Tidal marshes are threatened coastal ecosystems known for their capacity to store large amounts of carbon in their water-logged soils. Accurate quantification and mapping of global tidal marshes soil organic carbon (SOC) stocks is of considerable value to conservation efforts. Here, we used training data from 3710 unique locations, landscape-level environmental drivers and a global tidal marsh extent map to produce a global, spatially explicit map of SOC storage in tidal marshes at 30 m resolution.

Using lake sediments to assess the long-term impacts of anthropogenic activity in tropical river deltas.

Tropical river deltas, and the social-ecological systems they sustain, are changing rapidly due to anthropogenic activity and climatic change. Baseline data to inform sustainable management options for resilient deltas is urgently needed and palaeolimnology (reconstructing past conditions from lake or wetland deposits) can provide crucial long-term perspectives needed to identify drivers and rates of change. We review how palaeolimnology can be a valuable tool for resource managers using three current issues facing tropical delta regions: hydrology and sediment supply, salinisation and nutrient pollution.

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.

Purpose: In 2013, afatinib was approved for non-small-cell lung cancer with subsequent indication expansion. We investigated published afatinib clinical trials to assess risk and benefit profiles for the drug in its approved indication of non-small-cell lung cancer as well as in off-label uses. Previous literature demonstrates excessive patient burden and limited benefit as afatinib has spread into more indications.

Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials.

Objective: This study aims to evaluate published clinical trials of ramucirumab to assess the risk/benefit profile and burden over time for patients.

Background: The burden of oncologic drug development on patients paired with increasing clinical trial failure rates emphasizes the need for reform of drug development. Identifying and addressing patterns of excess burden can guide policy, ensure evidence-based protections for trial participants, and improve medical decision-making.